Research progress on application of immune checkpoint inhibitors in neoadjuvant treatment of melanoma
10.12354/j.issn.1000-8179.2025.20241411
- VernacularTitle:免疫检查点抑制剂在黑色素瘤新辅助治疗中的应用研究进展
- Author:
Du XIAOYU
1
;
Ma JIANGUO
;
Xia RENJIE
;
Yao WEIQING
;
Xu WEI
;
Ou SIYI
;
Wang DONGSHAN
;
Miao BAIWEN
;
Song LEI
;
Yan LONG
Author Information
1. 西北民族大学医学部(兰州市 730030);中国人民解放军联勤保障部队第九四〇医院肝胆外科/普通外科
- Publication Type:Journal Article
- Keywords:
melanoma;
immunotherapy;
neoadjuvant therapy;
combination treatment;
immune checkpoint inhibitors(ICIs)
- From:
Chinese Journal of Clinical Oncology
2025;52(2):86-91
- CountryChina
- Language:Chinese
-
Abstract:
As the application of immune checkpoint inhibitors(ICIs)in the perioperative treatment of melanoma is increasingly introduced at earlier stages,it presents a critical opportunity for the development and clinical translation of neoadjuvant therapy.The results of phaseⅠ/Ⅱ clinical trials on neoadjuvant ICI therapy for melanoma demonstrate that neoadjuvant ICIs effectively improve the pathologic re-sponse rate in melanoma patients.Recent studies have shown that combining ICIs with other treatment modalities,including radiotherapy,chemotherapy,and targeted therapies,can enhance antitumor efficacy of neoadjuvant treatment for patients with melanoma.Optimizing treatment regimens,managing adverse events,identifying and addressing pseudoprogression,and handling cases of oligoprogression have become key areas of research in incorporating ICI regimens into neoadjuvant treatment for patients with melanoma.The search for bio-markers to monitor immunotherapy efficacy is expected to become a major focus of future research.This article provides a review of the re-search progress,controversies,and challenges in the application of ICIs in the neoadjuvant treatment of melanoma,and discusses future re-search directions,aiming to offer insights into the clinical application and development of ICIs in melanoma neoadjuvant therapy.
